2024 |
Novo Nordisk - ADR
|
- |
57.1 M |
-16.3 % |
2023 |
Novo Nordisk - ADR
|
- |
68.2 M |
24.5 % |
2019 |
Novo Nordisk - ADR
|
- |
54.8 M |
32.7 % |
2018 |
Novo Nordisk - ADR
|
- |
41.3 M |
- |
2018 |
Novo Nordisk - ADR
|
- |
41.3 M |
- |
2007 |
Novo Nordisk - ADR
|
Executive Vice President, Quality, Regulatory and Business Development |
- |
- |
2006 |
Novo Nordisk - ADR
|
- |
1.8 M |
-62.5 % |
2006 |
Novo Nordisk - ADR
|
Executive Vice President, Quality, Regulatory and Business Development |
- |
- |
2005 |
Novo Nordisk - ADR
|
- |
4.8 M |
- |
2005 |
Novo Nordisk - ADR
|
Executive Vice President, Quality, Regulatory and Business Development |
4.8 M |
- |
2004 |
Novo Nordisk - ADR
|
- |
4.4 M |
- |
2004 |
Novo Nordisk - ADR
|
Executive Vice President, Quality, Regulatory and Business Development |
- |
- |
2003 |
Novo Nordisk - ADR
|
- |
- |
- |
2003 |
Novo Nordisk - ADR
|
- |
- |
- |